A Phase 1 interventional study of FXS6837 capsule in Hepatic Impairment, sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (part of Fosun Pharma) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a single-center, single-dose, parallel-group, open-label phase I clinical study to evaluate the safety, pharmacokinetics, and pharmacodynamics of FXS6837 between participants with mild and moderate hepatic impairment and participants with normal hepatic function
Approximately 24 participants with hepatic impairment and participants with normal hepatic function are planned to be enrolled into this study. Participants will undergo screening examinations from D-28 to D-1. Eligible participants will be admitted to the clinical study site on D-1. During the trial, participants will undergo laboratory tests, 12-lead ECG, vital sign observation, AE collection, and PK, PD, and plasma protein binding (PPB) sample collection.
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. is the lead sponsor of 37 studies on the registry; 23 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject is eligible to enter the study if:
Exclusion Criteria:
Subjects with hepatic impairment will not be eligible to participate in the study if any of the following exclusion criteria also apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arm 1:mild hepatic impairment, FXS6837 125mg orally once.
Drug: FXS6837 capsule
Arm 2: moderate hepatic impairment, FXS6837 125mg orally once.
Drug: FXS6837 capsule
Arm 3: normal hepatic function FXS6837 125mg orally once.
Drug: FXS6837 capsule
Mild hepatic impairment, FXS6837 125mg orally once.
Primary Pharmacokinetics(PK) parameter of FXS6837 in plasma:Cmax
Maximum observed concentration (Cmax)
Time frame: Up to Day 14
Primary PK parameter of FXS6837 in plasma: AUC0-t
Area under the plasma concentration-time curve from time 0 to time t (AUC0-t)
Time frame: Up to Day 14
Primary PK parameter of FXS6837 in plasma: AUC0-∞
area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞)
Time frame: Up to Day 14
Secondary PK parameter of FXS6837 in plasma: Tmax
Time to reach maximum concentration(Tmax)
Time frame: Up to Day 14
Secondary PK parameter of FXS6837 in plasma: t1/2
Half-life (t1/2)
Time frame: Up to Day 14
Secondary PK parameter of FXS6837 in plasma: CL/F
Apparent total plasma clearance (CL/F)
Time frame: Up to Day 14
Secondary PK parameter of FXS6837 in plasma: Vz/F
Apparent terminal volume of distribution (Vz/F)
Time frame: Up to Day 14
PK parameter of unbound FXS6837 in plasma: Cmax,u
Maximum unbound concentration (Cmax, u)
Time frame: Up to Day 14
PK parameter of unbound FXS6837 in plasma: AUC0-t, u
Area under the unbound plasma concentration-time curve from time 0 to time t (AUC0-t, u)
Time frame: Up to Day 14
PK parameter of unbound FXS6837 in plasma: AUC0-∞, u
Area under the unbound plasma concentration-time curve from time 0 to infinity (AUC0-∞, u)
Time frame: Up to Day 14
Incidence and severity of AE and SAE
Incidence and severity of adverse events (AEs)/serious adverse events (SAEs), including abnormalities in clinical symptoms and vital signs, physical examination, 12-lead electrocardiogram (ECG), and laboratory tests
Time frame: Up to Day 14
Pharmacodynamics indicator of FXS6837. Change from baseline in peripheral blood complement Alternative Pathway activity
Complement alternative pathway (AP) activity in peripheral blood.Complement alternative pathway (AP) activity will be measured in peripheral blood. Absolute change and percentage change from baseline to Day 5 will be assessed.
Time frame: Up to Day 5
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Apr 2027, 4 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. →